Oxford Nanopore has developed a new generation of nanopore-based sensing technology for faster, information-rich, accessible and affordable molecular analysis, used to understand and characterise the biology of humans and diseases such as cancer. By enabling biological insights, we strive to improve life on Earth and beyond.
We’re looking for a Senior Manager, Market Development EMEAI – Oncology to join our growing commercial team. In this role, the successful candidate will be responsible for driving commercial growth by expanding the total addressable oncology market for Oxford Nanopore Technologies across the EMEAI region. This role can be based in the UK, France, or Germany. Please note that this role involves frequent travel across EMEAI, minimum 50%.
The Details…
This role focuses on identifying and unlocking new customer segments, applications, and geographies, translating ONT’s unique sequencing capabilities into scalable, commercially impactful market opportunities. Working at the intersection of science, policy, and commercial strategy, this role partners closely with sales, marketing, product, medical, regulatory, and government affairs teams to accelerate adoption and long‑term revenue growth.
This role has a primary focus on high-value applications in Oncology and where Oxford Nanopore Technologies offers clear differentiation. The role will identify and validate priority market opportunities, develop strategic partnerships and evidence-generation programs, and support the progression of promising applications from research-stage use through operationalization and production-scale deployment.
This role is suited to a highly self‑directed builder who thrives in ambiguous environments and can create momentum ahead of fully scaled organisational infrastructure.
Key Responsibilities and Duties:
Market Expansion & Growth
- Identify, assess, and validate new market opportunities for ONT technologies across research, applied, and clinical customer segments.
- Develop and execute commercial‑forward market development strategies with clear milestones and measurable growth outcomes.
- Expand market access by enabling entry into new customer segments and geographies across EMEAI.
- Provide structured input into future product, workflow, and portfolio roadmaps based on market needs and evidence gaps.
Partnerships, KOL & Ecosystem Development
- Develop strategic partnerships and collaborations to enable entry into oncology and new applications.
- Build, engage, and develop Key Opinion Leaders (KOLs) and influencer networks aligned to ONT growth priorities.
- Lead community advocacy, education, and awareness initiatives to support market creation and adoption.
- Partner with academic, clinical, industry, and government stakeholders to strengthen ONT’s ecosystem presence.
Evidence Generation & Standards Shaping
- Define and execute evidence generation strategies, including gap analysis to support market entry for Oncology.
- Support development of scientific, clinical, and economic proof points that enable adoption and scale.
- Partner with thought leaders to influence professional societies, guidelines, and standards that maximize the impact of ONT technology.
- Translate evidence into compelling commercial and value‑based narratives for customers and stakeholders.
Clinical, Regulatory & Market Access Alignment
- Support regulatory, reimbursement, and market access pathways when entering or expanding clinical markets by applying knowledge of the region, leverage society engagement and standards.
- Work closely with regulatory, medical, and government affairs teams (where established), to align market development activities with policy and compliance requirements, being the key conduit with the customer in region and these teams to ensure clear objective are achieved and programs delivered.
- Enable customers operating in both regulated and unregulated environments through education and strategic guidance.
Commercial Enablement & Cross‑Functional Leadership
- Partner with regional commercial teams to support pipeline development, strategic deals, and complex opportunities.
- Enable sales and marketing teams through education, positioning, and strategic content tailored to oncology.
- Communicate market intelligence and customer insights to inform commercial strategy and execution.
- Operate effectively within a global, matrixed organization, influencing across functions and seniority levels.
Leadership & Capability Development
- Provide leadership and strategic direction to market development activities across EMEAI.
- Support capability building through training, coaching, and knowledge transfer.
- Foster collaboration, accountability, and execution discipline across cross‑functional teams.
- Drive cross‑regional alignment and knowledge‑sharing, partnering with global Market Development leaders across AMR, EMEAI and APAC to ensure consistency of strategy, prioritization, and execution as the global capability scales.
- Act as an early builder for the global Market Development function, contributing learnings, frameworks, and operating models that inform future role expansion across regions.
What We’re Looking For…
- Advanced degree (or equivalent experience) in genomics, molecular biology, life sciences or a related discipline.
- Extensive experience in genomics, life sciences, or healthcare technology, with strong exposure to commercial strategy and market development.
- Demonstrated success in creating or expanding markets, launching new collaborations and evidence generation studies, or enabling adoption of innovative technologies.
- Demonstrated experience in society engagement, white paper creation and participating/driving standards setting.
- Strong understanding of clinical, research, and applied genomics ecosystems in EMEAI.
- Proven ability to influence senior stakeholders and operate effectively in complex, matrixed environments.
- Demonstrated ability to operate effectively in lean or emerging organizational environments, building capability and momentum without reliance on established support functions.
- Strong personal network across relevant genomics, clinical, applied, or policy ecosystems, with the ability to independently open doors and create opportunities.
- Hands‑on mindset, with willingness to contribute directly to content development, stakeholder education, and early market‑shaping activities.
- High resilience and adaptability, with the ability to progress initiatives even when cross‑functional resources are limited or evolving.
Please note that no terminology in this advert is intended to discriminate on the grounds of a person's gender, marital status, race, religion, colour, age, disability or sexual orientation. Every candidate will be assessed only in accordance with their merits, qualifications and abilities to perform the duties of the job.
#LI-JR1
#LI-hybrid
About UsOxford Nanopore Technologies: Our goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. With a thriving culture of ambition and strong innovation goals, Oxford Nanopore is a UK headquartered company with global operations and customers in more than 125 countries.
Skills Required
- Advanced degree or equivalent experience in genomics, molecular biology, life sciences, or a related discipline
- Extensive experience in genomics, life sciences, or healthcare technology
- Strong exposure to commercial strategy and market development
- Demonstrated success creating or expanding markets, launching collaborations and evidence-generation studies, or enabling adoption of innovative technologies
- Experience with society engagement, white paper creation, and standards setting
- Strong understanding of clinical, research, and applied genomics ecosystems in EMEAI
- Ability to influence senior stakeholders in complex, matrixed environments
- Ability to build capability and momentum in lean or emerging organizations
- Strong personal network across genomics, clinical, applied, or policy ecosystems
- Hands-on willingness to develop content, educate stakeholders, and shape early markets
- High resilience and adaptability when cross-functional resources are limited or evolving
Oxford Nanopore Technologies Compensation & Benefits Highlights
The following summarizes recurring compensation and benefits themes identified from responses generated by popular LLMs to common candidate questions about Oxford Nanopore Technologies and has not been reviewed or approved by Oxford Nanopore Technologies.
-
Fair & Transparent Compensation — Pay is considered good to above average across many roles, with employer-provided ranges visible for several U.S. commercial and applications positions and company materials emphasizing market‑competitive base pay. Commercial and some senior technical posts, particularly in the U.S., are positioned as competitive and often paired with strong variable components.
-
Equity Value & Accessibility — All‑employee share plans in the UK and a U.S. employee stock purchase plan indicate broad access to equity as part of total reward. Company communications highlight attractive bonus and share plans that add meaningful upside beyond base pay.
-
Healthcare Strength — U.S. roles indicate strong health insurance and core protections, while official materials and country overviews reference private medical coverage and wellbeing support. These elements position the health package as a notable strength alongside cash compensation.
Oxford Nanopore Technologies Insights
What We Do
Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.








